PLGA nanoparticles as a platform for vitamin D-based cancer therapy

• Maria J. Ramalho,
• Joana A. Loureiro,
• Bárbara Gomes,
• Manuela F. Frasco,
• Manuel A. N. Coelho and
• M. Carmo Pereira

Beilstein J. Nanotechnol. 2015, 6, 1306–1318, doi:10.3762/bjnano.6.135

• dimethacrylate) microspheres with a size of about 35 μm [22]. In this project, the authors used cholecalciferol as a drug model for calcitriol. They demonstrated that their cholecalciferol-loaded microspheres are biocompatible, allowed for controlled and sustained release, and increased the efficiency of the

•  2. The prepared PLGA NPs exhibited an initial rapid release, followed by a slower, sustained release. As Figure 2 shows, calcitriol released at 24 h was around 46%. This initial rapid release might be attributed to the release of the surface-adsorbed vitamin. The calcitriol entrapped in the

• Holzer et al., where it was proven that this is a well-suited cryoprotectant [31]. PLGA NPs tend to exhibit a biphasic release pattern, characterized by an initial rapid release, followed by a slower sustained release [19]. As expected, the NPs exhibited a rapid release in the first 24 h due to the

Release behaviour and toxicity evaluation of levodopa from carboxylated single-walled carbon nanotubes

• Julia M. Tan,
• Jhi Biau Foo,
• Sharida Fakurazi and
• Mohd Zobir Hussein

Beilstein J. Nanotechnol. 2015, 6, 243–253, doi:10.3762/bjnano.6.23

• exhibited favourable, slow, sustained-release characteristics as a drug carrier with a release period over more than 20 h. The results obtained from the drug release studies of LD at different pH values showed that the LD-loaded nanohybrid is pH activated. The release kinetics of LD from SWCNT–COOH were

• carbon nanotubes; levodopa; MTT assay; nanomedicine; Parkinson’s disease; PC12 cells; sustained release; Introduction Over the past few years, the revolutionary development of nanomedicine has emerged as one of the most prominent research areas in biomedical science. This interdisciplinary technology is

• carriers for proteins and pharmaceuticals to treat diseases by Bangham and Horne in the 1960s [1]. Since then, multidisciplinary researchers have been actively investigating advanced drug delivery systems by directing drugs and/or carriers with sustained release properties directly to a the specific site

Magnetic-Fe/Fe₃O₄-nanoparticle-bound SN38 as carboxylesterase-cleavable prodrug for the delivery to tumors within monocytes/macrophages

• Hongwang Wang,
• Tej B. Shrestha,
• Matthew T. Basel,
• Raj K. Dani,
• Gwi-Moon Seo,
• Sivasai Balivada,
• Marla M. Pyle,
• Heidy Prock,
• Olga B. Koper,
• Prem S. Thapa,
• David Moore,
• Ping Li,
• Viktor Chikan,
• Deryl L. Troyer and
• Stefan H. Bossmann

Beilstein J. Nanotechnol. 2012, 3, 444–455, doi:10.3762/bjnano.3.51

• ][22][23][24][25][26]. SN38-loaded polymeric micelles (NK012) have been used in preclinical and clinical studies against various types of cancer. Specific accumulation of this formulation to the tumor site by the EPR effect (enhanced permeation and retention), and sustained release of SN38 in tumor